# A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

> **NCT03781934** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medivir** · enrollment: 53 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Intrahepatic Cholangiocarcinoma
- Liver Metastases

## Interventions

- **DRUG:** MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
- **DRUG:** MIV-818 (fostroxacitabine bralpamide) + lenvatinib

## Key facts

- **NCT ID:** NCT03781934
- **Lead sponsor:** Medivir
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-05
- **Primary completion:** 2025-01-07
- **Final completion:** 2025-06-16
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03781934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03781934, "A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03781934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*